Advertisement
Advertisement
May 20, 2013
CE Mark Granted for Sequent Medical's Web SL Family of Neurovascular Aneurysm Embolization Devices
May 20, 2013—Sequent Medical, Inc. (Aliso Viejo, CA) announced that it has received CE Mark approval for the SL (single-layer) family of Web aneurysm embolization devices and has commenced a controlled release of these new models in select neurovascular centers in Europe. The SL family offers a lower profile and excellent navigability that will enable physicians to treat a broader range of aneurysms with the Web platform, the company stated.
Sequent Medical advised that the Web is a low-porosity, intrasaccular neurovascular embolization device that is designed to bridge the neck of a ruptured or unruptured intracranial aneurysm and promote rapid periprocedural stasis. The Web enables physicians to treat a broad range of intracranial aneurysms with the familiarity of an intrasaccular approach while using established biomaterials.
According to Sequent Medical, the SL configurations are created with the company's MicroBraid technology, a dense mesh constructed from a large number of extremely fine nitinol wires. MicroBraid features a mix of wire diameters and high wire counts to achieve a tailored balance of compliance, porosity, and profile across device sizes. The SL family consists of two separate product configurations, the Web SL and Web SLS, each with a distinct shape designed to accommodate varying aneurysm morphologies. Both configurations are available in multiple sizes ranging from 4 mm to 11 mm and are designed for delivery through Sequent Medical's Via microcatheters.
“Sequent Medical has responded to physicians' requests in developing the Web SL configurations,” commented Prof. Laurent Pierot, MD, in the company's press release. Prof. Pierot is Head of the Department of Radiology at Maison Blanche Hospital in Reims, France. “The SL family promises to expand the range of aneurysms physicians can treat with the Web, while continuing to offer the familiar, straightforward procedure we've come to value with the Web DL.”
Advertisement
Advertisement